LOXL2 and familial pancreatic carcinoma: Simtuzumab has shown limited efficacy in patients with pancreatic cancer or KRAS-mutant colorectal cancer (47, 48), which may be due to the indirect and weak blocking effect of simtuzumab on the interaction of LOXL2 with PEAR1.